#METABOLOMICS WORKBENCH hormel101_20180712_130954 DATATRACK_ID:1442 STUDY_ID:ST001005 ANALYSIS_ID:AN001647 PROJECT_ID:PR000680 VERSION 1 CREATED_ON July 12, 2018, 5:24 pm #PROJECT PR:PROJECT_TITLE Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia PR:PROJECT_SUMMARY "Cachexia is a debilitating syndrome that results in severe, involuntary weight PR:PROJECT_SUMMARY loss due to the depletion of skeletal muscle mass. This syndrome occurs in a PR:PROJECT_SUMMARY majority of cancers and contributes to approximately one third of all cancer PR:PROJECT_SUMMARY deaths. Currently, no effective therapy exists to combat this malignant PR:PROJECT_SUMMARY disorder, and disappointing results from recent Phase III clinical trials PR:PROJECT_SUMMARY indicate that a cachexia treatment is not likely to appear soon. Thus, it is PR:PROJECT_SUMMARY clear that greater knowledge of the mechanisms driving muscle wasting in PR:PROJECT_SUMMARY cachexia is needed in order to identify new therapeutic targets and stimulate PR:PROJECT_SUMMARY new clinical trials. Our approach to gaining this knowledge has been to work PR:PROJECT_SUMMARY with muscle biopsies from pancreatic cancer patients, since this population is PR:PROJECT_SUMMARY highly prone to cachexia. We have also been expanding our studies beyond the PR:PROJECT_SUMMARY classical mouse models of cancer cachexia in hopes of finding a new model that PR:PROJECT_SUMMARY better recapitulates the human disease. We recently undertook RNA-Seq analysis PR:PROJECT_SUMMARY comparing muscle biopsies from pancreatic cancer patients with and without PR:PROJECT_SUMMARY cachexia, which has been exciting since this type of analysis has not yet been PR:PROJECT_SUMMARY performed in patient samples. Preliminary results revealed that cachectic muscle PR:PROJECT_SUMMARY was associated with alterations in metabolism. These data provide the rationale PR:PROJECT_SUMMARY for performing metabolomics to ascertain whether specific metabolic pathways or PR:PROJECT_SUMMARY metabolites can be identified as potential drivers of muscle wasting in cachexia PR:PROJECT_SUMMARY or be used as biomarker of cachexia, which the field desperately needs. An PR:PROJECT_SUMMARY additional need is a well-validated animal model of cancer cachexia that PR:PROJECT_SUMMARY accurately reflects the human condition, which can be used to test mechanisms PR:PROJECT_SUMMARY and pre-clinical compounds. We propose to perform these studies under the Mayo PR:PROJECT_SUMMARY Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) PR:PROJECT_SUMMARY Identify metabolic alterations and biomarkers of pancreatic cancer-induced PR:PROJECT_SUMMARY muscle wasting; and 2) Identify a suitable mouse model that recapitulates the PR:PROJECT_SUMMARY metabolic imbalance of muscles from pancreatic cancer cachexia patients. By PR:PROJECT_SUMMARY performing these studies, we will accelerate our understanding of the underlying PR:PROJECT_SUMMARY causes of muscle wasting, which should translate to improving the current PR:PROJECT_SUMMARY pipeline of anticachexia therapies. " PR:INSTITUTE Mayo Clinic PR:LAST_NAME Guttridge PR:FIRST_NAME Denis PR:ADDRESS 520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210 PR:EMAIL denis.guttridge@osumc.edu PR:PHONE 614-688-3137 #STUDY ST:STUDY_TITLE Amino Acid Concentrations in Muscle Tissue of Muscle Wasting in Cancer Cachexia ST:STUDY_TITLE (part I) ST:STUDY_SUMMARY Amino Acid Concentrations of Muscle Wasting in Cancer Cachexia. Muscle samples ST:STUDY_SUMMARY from 10 control patients, 10 weight stable pancreatic cancer patients, and 10 ST:STUDY_SUMMARY pancreatic cancer patients with significant weight loss. Samples are divided ST:STUDY_SUMMARY evenly between males and females. ST:INSTITUTE Mayo Clinic ST:LAST_NAME Guttridge ST:FIRST_NAME Denis ST:ADDRESS 520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210 ST:EMAIL denis.guttridge@osumc.edu ST:PHONE 614-688-3137 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - ms6644-1 Grouping:Weight Losing Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=128 SUBJECT_SAMPLE_FACTORS - ms6644-2 Grouping:Weight Losing Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=81 SUBJECT_SAMPLE_FACTORS - ms6644-3 Grouping:Weight Stable Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=91 SUBJECT_SAMPLE_FACTORS - ms6644-4 Grouping:Control Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=185 SUBJECT_SAMPLE_FACTORS - ms6644-5 Grouping:Control Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=265 SUBJECT_SAMPLE_FACTORS - ms6644-6 Grouping:Control Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=308 SUBJECT_SAMPLE_FACTORS - ms6644-7 Grouping:Weight Stable Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=105 SUBJECT_SAMPLE_FACTORS - ms6644-8 Grouping:Weight Stable Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=67 SUBJECT_SAMPLE_FACTORS - ms6644-9 Grouping:Control Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=196 SUBJECT_SAMPLE_FACTORS - ms6644-10 Grouping:Control Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=164 SUBJECT_SAMPLE_FACTORS - ms6644-11 Grouping:Weight Stable Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=264 SUBJECT_SAMPLE_FACTORS - ms6644-12 Grouping:Control Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=111 SUBJECT_SAMPLE_FACTORS - ms6644-13 Grouping:Weight Stable Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=136 SUBJECT_SAMPLE_FACTORS - ms6644-14 Grouping:Weight Losing Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=126 SUBJECT_SAMPLE_FACTORS - ms6644-15 Grouping:Weight Losing Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=112 SUBJECT_SAMPLE_FACTORS - ms6644-16 Grouping:Weight Stable Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=203 SUBJECT_SAMPLE_FACTORS - ms6644-17 Grouping:Control Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=163 SUBJECT_SAMPLE_FACTORS - ms6644-18 Grouping:Weight Losing Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=111 SUBJECT_SAMPLE_FACTORS - ms6644-19 Grouping:Weight Losing Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=139 SUBJECT_SAMPLE_FACTORS - ms6644-20 Grouping:Control Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=283 SUBJECT_SAMPLE_FACTORS - ms6644-21 Grouping:Weight Losing Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=93 SUBJECT_SAMPLE_FACTORS - ms6644-22 Grouping:Control Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=209 SUBJECT_SAMPLE_FACTORS - ms6644-23 Grouping:Weight Stable Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=206 SUBJECT_SAMPLE_FACTORS - ms6644-24 Grouping:Weight Losing Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=72 SUBJECT_SAMPLE_FACTORS - ms6644-25 Grouping:Control Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=315 SUBJECT_SAMPLE_FACTORS - ms6644-26 Grouping:Weight Stable Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=113 SUBJECT_SAMPLE_FACTORS - ms6644-27 Grouping:Weight Losing Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=215 SUBJECT_SAMPLE_FACTORS - ms6644-28 Grouping:Weight Losing Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=116 SUBJECT_SAMPLE_FACTORS - ms6644-29 Grouping:Weight Stable Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=135 SUBJECT_SAMPLE_FACTORS - ms6644-30 Grouping:Weight Stable Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=248 #COLLECTION CO:COLLECTION_SUMMARY Tissue and blood donated from Cancer Cachexia Program at Ohio State University CO:SAMPLE_TYPE Muscle #TREATMENT TR:TREATMENT_SUMMARY "Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, TR:TREATMENT_SUMMARY with the most notable symptom being unintentional weight loss. Cachectic TR:TREATMENT_SUMMARY patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss TR:TREATMENT_SUMMARY and its associated weakness contributing to the morbidity and mortality of these TR:TREATMENT_SUMMARY patients. Despite three decades of research into mechanisms driving muscle TR:TREATMENT_SUMMARY wasting due to cancer, to date, an approved pharmacological therapy to prevent TR:TREATMENT_SUMMARY or treat cancer cachexia is still lacking. Our laboratory focuses on cancer TR:TREATMENT_SUMMARY cachexia in patients with pancreatic cancer, as up to 85% of these patients TR:TREATMENT_SUMMARY experience weight loss. Cachexia often occurs early in the progression of TR:TREATMENT_SUMMARY pancreatic cancer, making clear that cachexia in these patients is not simply a TR:TREATMENT_SUMMARY result of end-stage disease. Further, with perhaps more than ΒΌ of all TR:TREATMENT_SUMMARY pancreatic cancer deaths resulting from muscle weakness as opposed to tumor TR:TREATMENT_SUMMARY burden, cachexia also significantly contributes to mortality due to pancreatic TR:TREATMENT_SUMMARY cancer. Because little progress has been made in improving treatment outcomes, TR:TREATMENT_SUMMARY addressing cancer-induced muscle wasting is perhaps the best strategy to prolong TR:TREATMENT_SUMMARY pancreatic cancer patient survival and increase patient quality of life. In an TR:TREATMENT_SUMMARY effort to better understand the mechanisms driving pancreatic cancer-induced TR:TREATMENT_SUMMARY muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a TR:TREATMENT_SUMMARY Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing TR:TREATMENT_SUMMARY attempted resection for pancreatic cancer or other abdominal surgeries have TR:TREATMENT_SUMMARY donated muscle and blood to our bank. A unique aspect of our tissue bank is our TR:TREATMENT_SUMMARY focus on patients eligible for resection. In contrast to other studies using TR:TREATMENT_SUMMARY patients with late-stage disease, our patients are not end-stage, as they are TR:TREATMENT_SUMMARY considered healthy enough to undergo a major operation. " #SAMPLEPREP SP:SAMPLEPREP_SUMMARY amino acids concentrations using muscle tissue #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Waters Acquity CH:COLUMN_NAME Waters Acquity BEH C18 (150 x 2.1mm, 1.7um) #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Thermo Quantum Ultra MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS nmoles/vial MS_METABOLITE_DATA_START Samples ms6644-1 ms6644-2 ms6644-3 ms6644-4 ms6644-5 ms6644-6 ms6644-7 ms6644-8 ms6644-9 ms6644-10 ms6644-11 ms6644-12 ms6644-13 ms6644-14 ms6644-15 ms6644-16 ms6644-17 ms6644-18 ms6644-19 ms6644-20 ms6644-21 ms6644-22 ms6644-23 ms6644-24 ms6644-25 ms6644-26 ms6644-27 ms6644-28 ms6644-29 ms6644-30 Factors Grouping:Weight Losing Grouping:Weight Losing Grouping:Weight Stable Grouping:Control Grouping:Control Grouping:Control Grouping:Weight Stable Grouping:Weight Stable Grouping:Control Grouping:Control Grouping:Weight Stable Grouping:Control Grouping:Weight Stable Grouping:Weight Losing Grouping:Weight Losing Grouping:Weight Stable Grouping:Control Grouping:Weight Losing Grouping:Weight Losing Grouping:Control Grouping:Weight Losing Grouping:Control Grouping:Weight Stable Grouping:Weight Losing Grouping:Control Grouping:Weight Stable Grouping:Weight Losing Grouping:Weight Losing Grouping:Weight Stable Grouping:Weight Stable Histidine 0.54 0.79 0.94 1.58 1.22 1.17 0.84 0.16 1.44 0.57 1.69 0.98 1.01 1.16 1.64 1.26 0.90 1.05 0.25 1.43 0.26 1.58 1.09 0.50 1.28 0.44 0.56 0.41 0.60 1.42 Hydroxyproline 0.06 0.09 0.09 0.14 0.11 0.11 0.07 0.01 0.27 0.13 0.19 0.10 0.13 0.04 0.08 0.08 0.10 0.12 0.07 0.15 0.03 0.17 0.15 0.10 0.08 0.13 0.06 0.08 0.03 0.14 1-Methylhistidine 0.000 0.075 0.000 0.026 0.000 0.000 0.000 0.000 0.040 0.058 0.000 0.000 0.000 0.042 0.037 0.000 0.000 0.000 0.000 0.000 0.030 0.000 0.079 0.026 0.000 0.047 0.000 0.035 0.000 0.062 3-Methylhistidine 0.013 0.035 0.000 0.044 0.029 0.031 0.019 0.000 0.079 0.024 0.014 0.029 0.016 0.022 0.016 0.013 0.043 0.000 0.000 0.033 0.011 0.037 0.020 0.000 0.041 0.033 0.008 0.035 0.000 0.019 Asparagine 0.44 0.57 0.44 0.69 0.67 0.99 0.59 0.17 0.53 0.55 0.80 0.39 0.48 0.64 0.51 0.40 0.49 0.44 0.41 0.91 0.25 0.66 0.55 0.52 0.69 0.43 0.64 0.42 0.19 0.87 Phosphoethanolamine 0.24 0.26 0.31 0.37 0.46 0.27 0.22 0.12 0.34 0.25 0.46 0.43 0.33 0.31 0.33 0.30 0.22 0.29 0.21 0.48 0.07 0.67 0.41 0.27 0.48 0.19 0.44 0.24 0.22 0.42 Arginine 0.98 1.75 2.62 1.77 2.00 1.70 1.94 0.37 2.46 2.08 1.69 1.12 2.19 1.82 1.63 1.05 1.45 0.84 0.99 2.77 1.08 1.27 1.28 1.20 1.49 1.12 1.42 1.19 0.56 1.25 Carnosine 12.50 5.24 2.76 10.87 5.44 13.30 6.02 1.32 11.23 16.22 18.47 8.23 5.55 12.46 6.48 7.26 13.83 16.35 6.47 12.02 4.95 8.34 19.73 14.78 16.56 5.76 18.58 7.16 2.41 12.03 Taurine 10.84 6.41 10.89 15.22 10.13 11.82 7.30 2.81 17.30 6.21 8.37 10.99 8.24 5.72 11.37 6.57 17.41 9.49 8.83 12.89 4.02 9.19 11.43 5.22 12.94 9.06 11.66 10.69 1.90 11.47 Anserine 0.31 0.10 0.04 0.15 0.11 0.23 0.08 0.03 0.23 0.29 0.21 0.15 0.07 0.29 0.19 0.10 0.15 0.37 0.11 0.15 0.09 0.12 0.21 0.19 0.23 0.11 0.16 0.08 0.04 0.13 Serine 1.20 1.20 0.79 1.31 1.39 1.46 0.78 0.30 0.60 1.40 1.21 0.86 0.59 0.92 1.03 0.64 0.86 0.91 0.67 1.07 0.67 1.18 0.96 0.81 0.96 0.67 1.15 0.66 0.31 1.49 Glutamine 17.48 27.22 29.87 21.18 42.98 38.08 11.96 3.93 21.25 18.50 24.80 10.44 16.94 24.45 14.86 11.89 28.44 13.41 14.11 27.05 11.11 21.81 22.37 19.45 25.90 13.78 17.55 21.79 5.95 32.11 Ethanolamine 0.04 0.03 0.03 0.06 0.07 0.06 0.04 0.01 0.06 0.04 0.06 0.04 0.04 0.03 0.04 0.06 0.04 0.04 0.02 0.06 0.02 0.06 0.05 0.05 0.06 0.02 0.05 0.04 0.02 0.08 Glycine 3.01 3.17 2.47 4.42 4.69 4.86 1.90 0.66 2.56 3.15 3.07 2.38 2.35 2.98 2.55 1.59 3.89 2.87 1.47 4.68 1.93 5.42 3.06 2.15 2.48 2.15 3.00 2.40 0.87 3.86 Aspartic Acid 0.54 0.96 0.91 0.37 0.65 0.76 0.32 0.15 0.05 0.33 1.07 0.37 0.59 0.78 0.23 0.17 0.31 0.24 0.11 0.64 0.14 0.26 0.64 0.42 0.63 0.41 0.56 0.17 0.07 0.28 Sarcosine 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.00 0.02 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.02 0.01 0.01 0.01 0.00 0.02 0.00 0.00 0.01 Citrulline 0.21 0.18 0.23 0.09 0.24 0.48 0.12 0.03 0.37 0.52 0.25 0.09 0.13 0.42 0.06 0.17 0.13 0.09 0.02 0.28 0.12 0.10 0.23 0.21 0.37 0.06 0.18 0.08 0.07 0.28 Glutamic Acid 2.37 2.23 4.65 3.38 2.76 4.02 1.83 0.60 3.47 1.76 3.48 1.91 3.43 1.48 2.16 1.83 2.54 0.77 2.53 1.83 0.68 5.07 1.94 1.28 3.29 1.99 2.03 2.13 0.55 1.80 beta-Alanine 0.31 0.15 0.15 0.80 0.19 0.32 0.27 0.09 0.38 0.06 0.64 0.42 0.36 0.34 0.97 0.68 0.26 0.43 0.15 0.37 0.02 0.50 0.38 0.18 0.26 0.26 0.30 0.19 0.47 0.18 Threonine 0.70 0.76 0.92 1.04 1.28 1.57 0.74 0.26 1.73 1.23 1.75 0.81 0.91 1.39 0.63 0.75 0.94 0.74 0.60 1.44 0.53 0.99 1.00 1.07 1.15 0.49 0.99 0.84 0.32 1.37 Alanine 3.72 5.95 3.26 6.68 3.78 6.63 4.94 1.46 6.32 6.67 9.76 4.20 6.64 4.91 6.29 5.02 5.52 4.78 3.53 9.33 3.16 7.89 8.46 5.69 8.20 3.14 7.34 4.76 2.14 8.29 gamma-Amino-N-butyric-acid 0.006 0.005 0.005 0.007 0.007 0.019 0.010 0.001 0.013 0.007 0.010 0.005 0.010 0.007 0.007 0.009 0.008 0.013 0.003 0.011 0.002 0.025 0.010 0.003 0.008 0.013 0.004 0.013 0.001 0.018 alpha-Aminoadipic-acid 0.076 0.028 0.223 0.092 0.201 0.081 0.132 0.003 0.118 0.050 0.140 0.046 0.135 0.126 0.094 0.046 0.093 0.021 0.090 0.091 0.074 0.079 0.049 0.073 0.120 0.061 0.081 0.074 0.013 0.123 beta-Aminoisobutyric-acid 0.007 0.015 0.001 0.006 0.017 0.031 0.013 0.002 0.011 0.009 0.004 0.002 0.004 0.004 0.010 0.020 0.008 0.002 0.001 0.017 0.006 0.009 0.009 0.002 0.010 0.017 0.007 0.003 0.001 0.005 Proline 0.72 1.49 2.57 1.26 2.17 1.82 1.04 0.34 2.28 2.41 2.36 1.40 1.57 1.21 1.23 1.34 1.02 1.49 0.90 1.90 0.70 2.51 1.83 1.42 1.65 0.69 1.18 0.88 0.51 1.53 Hydroxylysine 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hydroxylysine 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 alpha-Amino-N-butyric-acid 0.14 0.11 0.03 0.18 0.33 0.20 0.09 0.01 0.21 0.15 0.24 0.11 0.06 0.23 0.24 0.19 0.10 0.18 0.11 0.23 0.16 0.14 0.10 0.11 0.20 0.08 0.29 0.15 0.04 0.19 Ornithine 0.24 0.68 1.53 0.64 0.79 0.37 0.45 0.11 0.72 0.85 0.44 0.38 0.69 0.61 0.53 0.39 0.37 0.19 0.25 0.56 0.32 0.42 0.35 0.39 0.41 0.48 0.32 0.27 0.17 0.51 Cystathionine 1 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Cystathionine 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lysine 1.98 3.78 2.97 3.54 3.06 3.48 2.64 0.47 3.76 2.08 2.95 1.83 2.89 2.75 3.34 2.00 2.37 1.40 1.65 3.53 1.65 2.70 2.05 2.62 2.58 1.54 2.80 1.85 0.99 2.49 Cystine 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 Tyrosine 0.24 0.17 0.21 0.28 0.28 0.37 0.23 0.15 0.31 0.26 0.40 0.34 0.22 0.26 0.26 0.29 0.19 0.27 0.13 0.37 0.10 0.30 0.33 0.36 0.29 0.14 0.25 0.16 0.15 0.33 Methionine 0.11 0.08 0.10 0.15 0.17 0.18 0.12 0.07 0.16 0.17 0.20 0.18 0.10 0.14 0.13 0.16 0.12 0.13 0.07 0.23 0.05 0.18 0.20 0.18 0.16 0.06 0.15 0.09 0.08 0.17 Valine 0.40 0.35 0.45 0.77 0.77 0.51 0.45 0.18 0.69 0.62 0.76 0.63 0.37 0.48 0.52 0.71 0.49 0.52 0.32 0.70 0.23 0.72 0.77 0.65 0.89 0.25 0.58 0.48 0.28 0.79 Isoleucine 0.19 0.17 0.17 0.27 0.36 0.19 0.19 0.07 0.28 0.28 0.30 0.24 0.15 0.19 0.23 0.24 0.19 0.18 0.14 0.29 0.10 0.25 0.31 0.28 0.26 0.10 0.25 0.17 0.12 0.29 allo-Isoleucine 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.01 Homocystine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Leucine 0.37 0.27 0.33 0.56 0.69 0.44 0.36 0.17 0.51 0.42 0.56 0.55 0.31 0.37 0.44 0.51 0.39 0.41 0.26 0.70 0.18 0.58 0.59 0.55 0.62 0.20 0.47 0.37 0.23 0.62 Phenylalanine 0.22 0.15 0.19 0.26 0.27 0.31 0.24 0.13 0.28 0.20 0.34 0.34 0.21 0.21 0.23 0.28 0.21 0.22 0.14 0.38 0.09 0.35 0.27 0.28 0.31 0.12 0.25 0.16 0.15 0.32 Tryptophan 0.06 0.05 0.04 0.07 0.08 0.07 0.07 0.02 0.06 0.07 0.10 0.08 0.06 0.06 0.06 0.08 0.05 0.05 0.04 0.10 0.02 0.07 0.09 0.09 0.08 0.03 0.06 0.04 0.05 0.09 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Histidine Hydroxyproline 1-Methylhistidine 3-Methylhistidine Asparagine Phosphoethanolamine Arginine Carnosine Taurine Anserine Serine Glutamine Ethanolamine Glycine Aspartic Acid Sarcosine Citrulline Glutamic Acid beta-Alanine Threonine Alanine gamma-Amino-N-butyric-acid alpha-Aminoadipic-acid beta-Aminoisobutyric-acid Proline Hydroxylysine 1 Hydroxylysine 2 alpha-Amino-N-butyric-acid Ornithine Cystathionine 1 Cystathionine 2 Lysine Cystine Tyrosine Methionine Valine Isoleucine allo-Isoleucine Homocystine Leucine Phenylalanine Tryptophan METABOLITES_END #END